Ernexa Therapeutics Inc.
ERNA | NASDAQ
$3.96
+$0.13 (+3.39%)
At close: Sep 21, 2026, 4:00 PM ET
$3.96
$0 (0.00%)
Pre-market:
Sep 22, 2026, 8:05 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 582K | 68K | n/a | n/a | n/a |
Cost of Revenue | n/a | 96K | 236K | n/a | n/a | 98K |
Gross Profit | n/a | 486K | -168K | n/a | n/a | -98K |
Operating Income | -9.32M | -15.67M | -21.14M | -33.22M | -113.73M | -7.25M |
Interest Income | 83K | 249K | 138K | n/a | n/a | n/a |
Pretax Income | -14.13M | -44.51M | -21.67M | -24.53M | -122.48M | -26.53M |
Net Income | -14.08M | -44.54M | -21.67M | -24.58M | -122.55M | 11.91M |
Selling & General & Admin | 5.16M | 13.13M | 14.59M | 16.56M | 14.72M | 3.3M |
Research & Development | 4.16M | 4.6M | 5.92M | 10.39M | 12.71M | 3.95M |
Other Expenses | n/a | -1.58M | 461K | 6.27M | 86.3M | -98K |
Operating Expenses | 9.32M | 16.16M | 20.97M | 33.22M | 113.73M | 7.15M |
Interest Expense | 27K | 6.75M | 614K | 30K | 74K | 43K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.32M | 16.26M | 21.2M | 33.22M | 113.73M | 7.25M |
Income Tax Expense | -45K | 30K | -3K | 45K | 64K | n/a |
Shares Outstanding (Basic) | 252.28K | 1.14M | 212.56K | 122.04K | 86.6K | 69.31K |
Shares Outstanding (Diluted) | 252.28K | 1.14M | 212.56K | 122.04K | 86.6K | 69.31K |
EPS (Basic) | -56 | -39.25 | -102 | -201.50 | -1.42K | -87.75 |
EPS (Diluted) | -56 | -39.25 | -102 | -201.50 | -1.42K | -87.75 |
EBITDA | -13.84M | -36.12M | -19.93M | -24.01M | -121.95M | -26.39M |
EBIT | -14.1M | -37.76M | -21.06M | -24.5M | -122.41M | -26.49M |
Depreciation & Amortization | 263K | 1.64M | 1.12M | 497K | 459K | 98K |
Add to Watchlist
Select watchlists to add or remove ERNA